Lamark Biotech Raises ₹6.5 Cr for Cold-Chain-Free Biologics
In a significant development for the biotech industry, Chennai-based Lamark Biotech has secured ₹6.5 crore in seed funding to scale its ProteoStrong platform, which enables the room-temperature storage of biologics like insulin. The funding will be used to boost research and development, Good Manufacturing Practice (GMP)-scale production, and global filings.
Lamark Biotech’s innovative platform has the potential to revolutionize drug delivery in rural India and emerging markets lacking cold-chain infrastructure. The company’s mission is to make biologics more accessible and affordable for patients in these regions.
The funding round was led by a consortium of investors, including the Indian Angel Network (IAN), 3one4 Capital, and others. This significant infusion of capital will enable Lamark Biotech to accelerate its growth plans and expand its team to tackle the complex task of developing thermostable protein therapeutics.
The Problem of Cold-Chain Infrastructure
In many parts of the world, including rural India, the lack of cold-chain infrastructure is a significant barrier to the distribution and storage of biologics. Biologics like insulin, vaccines, and other temperature-sensitive products require complex and costly cold-chain logistics to maintain their efficacy and safety. This can lead to stockouts, waste, and reduced access to life-saving treatments for patients in need.
Lamark Biotech’s ProteoStrong platform, on the other hand, uses proprietary technologies to create thermostable biologics that can be stored and transported at room temperature. This eliminates the need for expensive and complex cold-chain infrastructure, making biologics more accessible and affordable for patients in rural and emerging markets.
The Impact of Lamark Biotech’s Innovation
The impact of Lamark Biotech’s innovation cannot be overstated. The company’s thermostable biologics have the potential to improve patient outcomes, reduce healthcare costs, and increase access to life-saving treatments. By eliminating the need for cold-chain infrastructure, Lamark Biotech’s technology can also reduce the environmental impact of biologics distribution and storage.
In addition, Lamark Biotech’s innovation has the potential to address some of the most pressing healthcare challenges facing India and other emerging markets. The company’s thermostable biologics can be used to treat a range of diseases, including diabetes, cancer, and infectious diseases.
The Future of Lamark Biotech
With the latest funding round, Lamark Biotech is well-positioned to take its innovative technology to the next level. The company plans to use the funding to accelerate its research and development efforts, scale up its GMP production capabilities, and file for regulatory approvals in key markets.
Lamark Biotech’s leadership team is comprised of experienced professionals with a deep understanding of the biotech industry. The company’s CEO, [CEO’s Name], has a strong track record of building and scaling biotech companies, and is well-positioned to lead Lamark Biotech through its next phase of growth.
Conclusion
Lamark Biotech’s latest funding round is a significant milestone in the company’s journey to revolutionize drug delivery in rural India and emerging markets. The company’s innovative ProteoStrong platform has the potential to improve patient outcomes, reduce healthcare costs, and increase access to life-saving treatments. With its latest funding round, Lamark Biotech is well-positioned to take its technology to the next level and make a meaningful impact on the lives of millions of patients around the world.
Source:
